Insulet Corp (PODD) appears to be a focus of stock movement as the company seems to be performing well. Various investment funds and institutional investors have increased, initiated, or reduced their shareholdings. Several influential brokers, such as UBS and Evercore ISI group, issued buy ratings and outperform recommendations on PODD. Insulet's Q2 2025 report showed that revenues surged by 32.9% to $649M, prompting the company to raise its full-year guidance. Additionally, its stock price enjoyed benefits from the FDA's approval for enhancements on
Omnipod 5. Canaccord Genuity raised its price target for Insulet Corporation (PODD) to $399, later increasing it to $450. Financial analysts also see Insulet as a strong growth and momentum stock, despite occasional falls in the stock price, due to overall market weakness and investor sentiment. Several headlines pointed out some selling activity from insiders and institutions, but this seems more balanced by the buy interest in its stock. Even the CEO's bold layout for
Omnipod 6 and innovation roadmap suggests a positive future. It’s underperforming Nasdaq, but considering its potential for long-term growth, now might be a good time to buy.
Insulet Corporation PODD News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 20 Dec 2025 14:09:34 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 2
